High prevalence of somatic oncogenic driver alterations, which cooperate with constitutional TP53 variants, provide rationale for exploiting oncogene addiction to achieve curative cancer therapies in LFS patients (Mezquita et al. 2020). Here, TP53 is linked to cancer.